{"id":"fludarabine-mono","safety":{"commonSideEffects":[{"rate":"60-80","effect":"Myelosuppression (neutropenia, thrombocytopenia, anemia)"},{"rate":"30-50","effect":"Infection"},{"rate":"20-40","effect":"Nausea and vomiting"},{"rate":"15-25","effect":"Fever"},{"rate":"10-20","effect":"Fatigue"},{"rate":"5-15","effect":"Neurotoxicity (peripheral neuropathy, confusion)"},{"rate":"5-10","effect":"Tumor lysis syndrome"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fludarabine monophosphate is a fluorinated nucleotide analog that is phosphorylated intracellularly and incorporated into DNA, disrupting DNA synthesis and repair. It is particularly effective against lymphoid malignancies because lymphocytes have high levels of deoxycytidine kinase, the enzyme required for its activation, making them more sensitive to the drug's cytotoxic effects than other cell types.","oneSentence":"Fludarabine is a purine analog that inhibits DNA synthesis by blocking ribonucleotide reductase and incorporating into DNA, leading to cell death in rapidly dividing lymphocytes.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:46:51.036Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic lymphocytic leukemia (CLL)"},{"name":"Follicular lymphoma"},{"name":"Small lymphocytic lymphoma (SLL)"}]},"trialDetails":[{"nctId":"NCT04673617","phase":"PHASE1, PHASE2","title":"AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Artiva Biotherapeutics, Inc.","startDate":"2021-03-29","conditions":"Non Hodgkin Lymphoma","enrollment":45},{"nctId":"NCT04776850","phase":"EARLY_PHASE1","title":"Pre-transplant Immunosuppression and Donor Stem Cell Transplant for the Treatment of Severe Hemoglobinopathies","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-12-29","conditions":"Beta Thalassemia Major, Sickle Beta 0 Thalassemia, Sickle Beta Plus Thalassemia","enrollment":""},{"nctId":"NCT05138458","phase":"PHASE1, PHASE2","title":"A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory TCL","status":"SUSPENDED","sponsor":"Myeloid Therapeutics","startDate":"2021-12-15","conditions":"Lymphoma, T-Cell, Peripheral, Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides","enrollment":40},{"nctId":"NCT01256398","phase":"PHASE2","title":"Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2010-12-14","conditions":"Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","enrollment":66},{"nctId":"NCT01946373","phase":"PHASE1","title":"T Cell Transfer With or Without Dendritic Cell Vaccination in Patients With Melanoma","status":"UNKNOWN","sponsor":"Karolinska University Hospital","startDate":"2013-10","conditions":"Melanoma","enrollment":20},{"nctId":"NCT00281892","phase":"PHASE3","title":"Fludarabine and Darbepoetin Alfa in Treating Older Patients With Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"German CLL Study Group","startDate":"2004-09","conditions":"Chronic Lymphocytic Leukemia, Anemia","enrollment":97}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":15,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Fludarabine mono","genericName":"Fludarabine mono","companyName":"German CLL Study Group","companyId":"german-cll-study-group","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Fludarabine is a purine analog that inhibits DNA synthesis by blocking ribonucleotide reductase and incorporating into DNA, leading to cell death in rapidly dividing lymphocytes. Used for Chronic lymphocytic leukemia (CLL), Follicular lymphoma, Small lymphocytic lymphoma (SLL).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}